BEAM vs NTLA
BEAM and NTLA side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BEAMBeam Therapeutics Inc. | NTLAINTELLIA THERAPEUTICS, INC. |
|---|---|---|
| Market cap | $2.71B | $1.52B |
| P/B | 2.32 | — |
| P/S | 19.4x | 22.5x |
| Revenue | $164.01M(TTM) | — |
| Revenue growth (YoY) | 120.0% | 16.9% |
| Net income | -$65.98M(TTM) | — |
| Earnings growth (YoY) | 78.8% | 20.5% |
| EPS, diluted | $-0.49(TTM) | — |
| EBIT margin | -274.6% | -651.7% |
| ROE | -6.9% | -66.5% |
| ROIC | -39.3% | — |
| 1y total return | +26.9% | -9.5% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: BEAM frente a NTLA
| Métrica | BEAM | NTLA |
|---|---|---|
| Valor final | $14.0K | $7.7K |
| Retorno total | +40.4% | -22.8% |
| CAGR | +5.4% | -3.9% |
| Volatilidad | 80.2% | 83.8% |
| Sharpe | 0.41 | 0.32 |
| Sortino | 0.64 | 0.49 |
| Caída máxima | -89.1% | -96.5% |
Basado en 1620 días de negociación comunes, 2020-02-06 → 2026-07-20 · tasa libre de riesgo 3.86% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)